Contact: Kathryn Ryan, 914-740-2100, email@example.com
New Method for Significantly Reducing Tumorigenicity in Induced Pluripotent Stem-Cell Based Therapies
New Rochelle, NY, July 23, 2014 – The potential for clinical use of induced pluripotent stem cell (iPSC) technology for transplant-based therapeutic strategies has previously been hindered by the risk of dysregulated cell growth, specifically the development of tumors. The ability to use etoposide treatment to halt teratoma formation in iPSCs for the treatment of heart disease, specifically acute myocardial infarction, is demonstrated in an article in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Stem Cells and Development website.
In the article “Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy” Saranya Wyles, Andre Terzic, Timothy Nelson, and coauthors, Mayo Clinic (Rochester, MN), discovered a strategy that alone or in conjunction with other methods could significantly reduce the risk of a tumorigenic event occurring. Their work demonstrates how pretreatment with genotoxic etoposide significantly lowered the threat of abnormal growths by removing the contaminated pluripotent cells and establishing an adjunctive therapy to further harness the clinical value of iPSC-derived cardiac regeneration.
“For anyone seeking to exploit iPSC technology in a clinical setting, the Mayo Clinic has described a strategy that significantly mitigates the risk of tumor development. Furthermore, the paper provides benchmark strategies for assessing the localization and persistence of cell-based treatments in a preclinical model," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. Complete tables of content and a free sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.